High-Throughput Platform for Identifying Stem Cell Toxicity
用于识别干细胞毒性的高通量平台
基本信息
- 批准号:8404019
- 负责人:
- 金额:$ 49.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-12-23 至 2015-10-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdultAnimalsAstrocytesAstrocytomaBiochemicalBiological AssayBiological ModelsBiotechnologyCell Culture SystemCell Culture TechniquesCell Differentiation processCell LineCell SurvivalCellsChemical EngineeringChemicalsDevelopmentDrug toxicityEngineeringEnvironmentEnvironmental HealthEvaluationExposure toExtracellular MatrixGlial Fibrillary Acidic ProteinGoalsGrowthHealthHomeostasisHumanHuman bodyImmunofluorescence ImmunologicIn VitroIndividualMAP Kinase GeneMesenchymal Stem CellsMethodsNatureNeuronsOrganOsteocalcinOutcomeOutcome StudyPathway interactionsPerformancePharmaceutical PreparationsPhasePlayPoisonPropertyResearchResourcesRoleSafetySeriesSignal PathwayStagingStem cellsTechniquesTechnologyTestingTissuesToxic effectToxicologyTransformed Cell LineTransport ProcessWorkadult stem cellbasebiochipcell behaviorcell typecombinatorialcytotoxicitydrug candidatedrug discoveryenvironmental chemicalhigh throughput screeninghuman adult stem cellhuman stem cellsin vivonerve stem cellnestin proteinresponsescreeningself-renewalstem cell biologystem cell differentiationstem cell fatestem cell nichetooltoxicant
项目摘要
DESCRIPTION (provided by applicant): The characterization and safety assessment of drugs, drug candidates, environmental chemicals, etc. requires extensive resources, particularly when animal studies are employed. Thus, there is a need to develop new in vitro techniques to predict which compounds pose an increased threat to human health and should therefore be prioritized for further screening and evaluation. Because of the critical role self-renewing stem cells play in tissue function and homeostasis, retention of healthy adult stem cells is crucial for human health. Nevertheless, the different responses of human stem cells compared with terminally differentiated cell types (e.g., primary and transformed cell lines) against drugs, drug candidates, and chemicals have been only sparsely studied. Such information would be vital to identify the toxic effects of such chemicals on the human body and in specific organs. We hypothesize that stem cells may behave in a fundamentally different way from the differentiated cells often used for toxicity studies, and we will address this hypothesis through the use of appropriate model systems. An outcome of this study, then, is that toxicity studies must be expanded to include stem cells, or drugs will proceed into trials with missing and even misleading toxicity information. To test this hypothesis, we propose to develop a high-throughput, microscale 3D cell-based screening tool that will enable rapid and highly quantitative information to be obtained on the effects of drugs, drug candidates, and chemical toxicants on human stem cells; specifically neural stem cells (NSCs) in comparison to adult primary and transformed neural cells, and human mesenchymal stem cells (MSCs). The specific aims of the proposed work are to: 1. Establish a robust 3D cell culture chip platform to grow and differentiate NSCs and MSCs; 2. Perform combinatorial in vitro extracellular matrix development; 3. Develop high-throughput on-chip assays of key signaling pathways in NSCs and MSCs that are critical in proliferation (self-renewal) and differentiation; 4. Validate the 3D cell culture microarray platform for cytotoxicity of stem cells in comparison to terminally differentiated primary cells and transformed cell lines using a series of reference compounds. This information is essential for the development of high throughput predictive toxicology screens for drug discovery and the prioritization of environmental chemicals based on their potential human toxicity.
描述(由申请人提供):对药物,候选药物,环境化学品等的表征和安全评估需要广泛的资源,尤其是在使用动物研究时。因此,有必要开发新的体外技术来预测哪种化合物对人类健康构成更大的威胁,因此应优先考虑进一步筛查和评估。由于自我更新干细胞在组织功能和稳态中起着至关重要的作用,因此健康的成年干细胞的保留对于人类健康至关重要。然而,与药物,候选药物和化学物质的终末分化细胞类型(例如原发性和转化的细胞系(例如,原发性和转化的细胞系)相比,人类干细胞的不同反应仅进行了稀疏研究。此类信息对于确定此类化学物质对人体和特定器官的毒性作用至关重要。我们假设干细胞可能以与经常用于毒性研究的分化细胞根本不同的方式行为,我们将通过使用适当的模型系统来解决这一假设。因此,这项研究的结果是,必须扩大毒性研究以包括干细胞,否则药物将继续进行具有缺失甚至具有误导性毒性信息的试验。为了检验这一假设,我们建议开发一种基于微观的3D细胞筛查工具,该工具将使可以快速,高度定量的信息在药物,候选药物和化学毒物对人干细胞的影响方面获得。与成人原代和转化的神经细胞以及人间充质干细胞(MSC)相比,特定于神经干细胞(NSC)。拟议的工作的具体目的是:1。建立一个强大的3D细胞培养芯片平台,以生长和区分NSC和MSC; 2。进行组合体外细胞外基质发育; 3。开发在NSC和MSC中关键信号通路的高通量在芯片上,这对于增殖至关重要(自我更新)和分化; 4。与使用一系列参考化合物相比,验证了3D细胞培养微阵列平台,以验证干细胞的细胞毒性和终末分化的原代细胞和转化细胞系。 此信息对于开发高通量预测毒理学筛查以发现药物发现和基于其潜在人类毒性的环境化学物质的优先次序。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jonathan S. Dordick其他文献
Endolysin-based autolytic E. coli system for facile recovery of recombinant proteins
基于内溶素的自溶大肠杆菌系统,可轻松回收重组蛋白
- DOI:
10.1021/acs.jafc.1c00059 - 发表时间:
2021 - 期刊:
- 影响因子:6.1
- 作者:
Jian Zha;Zhiqiang Liu;Runcong Sun;Guoli Gong;Jonathan S. Dordick;Xia Wu - 通讯作者:
Xia Wu
Facile pretreatment of lignocellulosic biomass at high loadings in room temperature ionic liquids
在室温离子液体中高负载量轻松预处理木质纤维素生物质
- DOI:
10.1002/bit.23266 - 发表时间:
2011-12 - 期刊:
- 影响因子:3.8
- 作者:
Hong Wu;Mauricio Mora-Pale;Jian-Jun Miao;Thomas V. Doherty;Robert J. Linhardt;Jonathan S. Dordick - 通讯作者:
Jonathan S. Dordick
Jonathan S. Dordick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jonathan S. Dordick', 18)}}的其他基金
Remote Electromagnetic Control of Neural Activity for Treatment of Parkinson's Disease
神经活动的远程电磁控制治疗帕金森病
- 批准号:
9890014 - 财政年份:2016
- 资助金额:
$ 49.38万 - 项目类别:
High-Throughput Platform for Identifying Stem Cell Toxicity
用于识别干细胞毒性的高通量平台
- 批准号:
8217894 - 财政年份:2011
- 资助金额:
$ 49.38万 - 项目类别:
High-Throughput Platform for Identifying Stem Cell Toxicity
用于识别干细胞毒性的高通量平台
- 批准号:
8573021 - 财政年份:2011
- 资助金额:
$ 49.38万 - 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
- 批准号:
8294884 - 财政年份:2009
- 资助金额:
$ 49.38万 - 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
- 批准号:
8016845 - 财政年份:2009
- 资助金额:
$ 49.38万 - 项目类别:
An Artificial Golgi: Controlled GAG Synthesis and Screening
人工高尔基体:受控 GAG 合成和筛选
- 批准号:
7945295 - 财政年份:2009
- 资助金额:
$ 49.38万 - 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
- 批准号:
7699173 - 财政年份:2009
- 资助金额:
$ 49.38万 - 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
- 批准号:
7904164 - 财政年份:2009
- 资助金额:
$ 49.38万 - 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
- 批准号:
8463596 - 财政年份:2009
- 资助金额:
$ 49.38万 - 项目类别:
Development of a Bioengineered Heparin from a Non-Animal Source
开发非动物来源的生物工程肝素
- 批准号:
8080427 - 财政年份:2009
- 资助金额:
$ 49.38万 - 项目类别:
相似国自然基金
成人型弥漫性胶质瘤患者语言功能可塑性研究
- 批准号:82303926
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
- 批准号:82302160
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
成人免疫性血小板减少症(ITP)中血小板因子4(PF4)通过调节CD4+T淋巴细胞糖酵解水平影响Th17/Treg平衡的病理机制研究
- 批准号:82370133
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
- 批准号:82302025
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
- 批准号:82302311
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Effects of tACS on alcohol-induced cognitive and neurochemical deficits
tACS 对酒精引起的认知和神经化学缺陷的影响
- 批准号:
10825849 - 财政年份:2024
- 资助金额:
$ 49.38万 - 项目类别:
A HUMAN IPSC-BASED ORGANOID PLATFORM FOR STUDYING MATERNAL HYPERGLYCEMIA-INDUCED CONGENITAL HEART DEFECTS
基于人体 IPSC 的类器官平台,用于研究母亲高血糖引起的先天性心脏缺陷
- 批准号:
10752276 - 财政年份:2024
- 资助金额:
$ 49.38万 - 项目类别:
Endothelial Cell Reprogramming in Familial Intracranial Aneurysm
家族性颅内动脉瘤的内皮细胞重编程
- 批准号:
10595404 - 财政年份:2023
- 资助金额:
$ 49.38万 - 项目类别:
Activity-dependent endocannabinoid control in epilepsy
癫痫的活动依赖性内源性大麻素控制
- 批准号:
10639147 - 财政年份:2023
- 资助金额:
$ 49.38万 - 项目类别:
REVAMP-PH: REpurposing Valsartan May Protect against Pulmonary Hypertension
REVAMP-PH:重新利用缬沙坦可以预防肺动脉高压
- 批准号:
10642368 - 财政年份:2023
- 资助金额:
$ 49.38万 - 项目类别: